Goldenwell Biotech (GWLL) Other Non-Current Liabilities (2022 - 2025)
Goldenwell Biotech filings provide 4 years of Other Non-Current Liabilities readings, the most recent being $189250.0 for Q3 2025.
- On a quarterly basis, Other Non-Current Liabilities fell 11.91% to $189250.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $189250.0, a 11.91% decrease, with the full-year FY2024 number at $189250.0, up 170.36% from a year prior.
- Other Non-Current Liabilities hit $189250.0 in Q3 2025 for Goldenwell Biotech, roughly flat from $189250.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $214838.0 in Q2 2024 to a low of $20000.0 in Q4 2022.
- Median Other Non-Current Liabilities over the past 4 years was $177419.0 (2024), compared with a mean of $135188.7.
- Biggest five-year swings in Other Non-Current Liabilities: soared 329.68% in 2024 and later decreased 11.91% in 2025.
- Goldenwell Biotech's Other Non-Current Liabilities stood at $20000.0 in 2022, then soared by 250.0% to $70000.0 in 2023, then soared by 170.36% to $189250.0 in 2024, then changed by 0.0% to $189250.0 in 2025.
- The last three reported values for Other Non-Current Liabilities were $189250.0 (Q3 2025), $189250.0 (Q2 2025), and $189250.0 (Q1 2025) per Business Quant data.